Avid Bioservices Expands Biologics Manufacturing Capacity
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), has started the second phase of the company’s two-phase effort to expand the overall manufacturing capacity of its Myford facility in California, the company announced on Feb. 22, 2021. A second manufacturing train with both upstream and downstream processing suites, known as Myford South, will be completed in 18 to 24 months, the company estimates.
The project’s first phase, started in the fourth quarter of 2020, expands the production capacity of the company’s existing manufacturing train within the northern side of the Myford facility by adding a second downstream processing suite. This phase will take approximately 12 to 15 months to complete, the company estimates.
“With the continued strong growth that we have experienced in both revenue and customer demand in recent months and quarters, we feel that Avid is in a strong position to kick off the second phase of our Myford facility expansion,” said Nicholas Green, president and CEO of Avid Bioservices, in the press release.
Source: Avid Bioservices
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
